US Tariffs Cut to 18%. These 6 Pharma Stocks Got Zero Duty.

While everyone focused on the headline — US reciprocal tariffs on India cut from 50% to 18% — the real story was buried in the fine print: generic pharmaceuticals got zero-duty access to the American market.

India is already the pharmacy of the world, supplying 40% of US generic drug demand. Now the tariff wall just disappeared. Here are six companies whose filings show they're positioned to capture this windfall.

1. Dr. Reddy's (DRREDDY) — North America is already their growth engine

Dr. Reddy's Q3 FY24 results are explicit: "YoY growth was primarily driven by market share gains for our existing products in North America." Their North America revenue hit Rs 32 billion in Q1 FY24 alone — a 79% YoY jump. With zero tariffs, their 50+ ANDA pipeline becomes even more profitable per unit shipped.

2. Sun Pharma (SUNPHARMA) — 541 approved ANDAs, 109 more pending

Sun Pharma's filings reveal the sheer scale of their US presence: 541 approved ANDAs for generic products, with 109 more awaiting FDA approval. Add 51 approved NDAs for specialty products. With zero duty, Sun's US pricing power improves — they can either maintain margins and undercut competitors, or hold prices and pocket the tariff savings.

3. Gland Pharma (GLAND) — 270 approved ANDAs, injectable specialist

Gland Pharma's quarterly results show 337 ANDA filings in the US, with 270 approved. Their US revenue contributed over 50% of total group revenue. As an injectable specialist, their products are harder to substitute and command better pricing. Zero tariffs on an already-dominant position means pure margin expansion.

4. Alembic Pharma (APLLTD) — 246 ANDAs filed, 178 approved

Alembic's filings show a 16% CAGR in US revenue over five years, with 117 products launched. They noted "Ex-US driven by partnership, delivered impressive CAGR of 28%." With zero duty, their run rate of 4 ANDA filings and 9 approvals per quarter becomes an accelerating revenue machine.

5. Caplin Point (CAPLIPOINT) — Small cap, big US ambitions

Caplin Point is the dark horse. Their filings reveal they planned to "launch own label in the US by Q1FY24 for 3 approved products" with 9 ANDAs under FDA review. They're building complex product capabilities — 3 injectables and 1 ophthalmic product ready for filing. Zero tariffs lower the barrier for smaller players to compete.

6. Glenmark Pharma (GLENMARK) — 46 applications pending with US FDA

Glenmark's filings show 46 applications in various stages of FDA approval, including 21 Paragraph IV applications (first-to-file generics that get 180-day market exclusivity). Para IV filings are particularly valuable under zero tariffs — the exclusivity period now comes with zero duty drag.

What retail investors should do

India's pharma sector was already winning in the US. Zero tariffs don't change the competitive landscape overnight — but they improve unit economics for every single shipment. Watch for these companies to report expanding US margins in their Q4 results.